A study to find the role of lignocaine given in intravenous route to manage the pain of fibromyalgia patients.
Phase 4
- Conditions
- Health Condition 1: M797- Fibromyalgia
- Registration Number
- CTRI/2019/08/020614
- Lead Sponsor
- ESI Institute of Pain Management
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients suffering from fibromyalgia with Widespread Pain Index(WPI)more than 7 and Symptom Severity Index(SSS) more than 5 or WPI 4-6 and SSS more than 9
2. Duration of fibromyalgia more than 12 weeks
3. Patient taking anti-neuropathic medicine more than 4 weeks
4. Degree of pain more than 5 according to VAS
Exclusion Criteria
1. Patients with allergy to lignocaine
2. History of cardiac dysrrythmias
3. Patients with severe hepatic and renal disease
4. Patients not giving consent
5. Poorly controlled psychiatric conditions with possible secondary gain or severe comorbidity.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Widespread Pain Index(WPI) and Symptom Severity Index(SSS)Timepoint: will be noted prior to the procedure and 1, 4 and 6 weeks after the procedure.
- Secondary Outcome Measures
Name Time Method Brief Pain Inventory(BPI) scoreTimepoint: will be noted prior to the procedure and 1, 4 and 6 weeks after the procedure.;Pain score using Visual Analogue ScaleTimepoint: will be noted prior to the procedure and 1, 4 and 6 weeks after the procedure.